JASPER — Indiana Department of Health reported 29 new COVID-19 cases in Dubois County Monday evening, for a total 11,696 cases including 152 deaths among 30,713 people tested.

The county’s seven-day rolling positivity rate is at 40% for all tests and 53.1% among people tested for the first time.

Slightly more than 60% of Dubois County’s eligible population is fully vaccinated.

Anyone age 5 and older is eligible to receive vaccine free of charge, although the Pfizer brand is the only vaccine recommended for ages 5-17.

Local resources

Vaccines are offered at CVS locations in Ferdinand, Huntingburg and Jasper; at Huntingburg Clinic (ages 5-11 only); at Dubois County Health Department; Walgreens Pharmacy in Jasper; and Walmart pharmacy in Jasper.

Memorial Hospital and Health Care Center offers Monoclonal antibody treatment Walmart pharmacy in Jasper offers Merck antiviral treatments. The state reports treatments are in limited supply.

COVID-19 testing is available at CVS pharmacies in Ferdinand, Huntingburg and Jasper; at Dubois County Health Department and at Memorial Hospital urgent car. Visit coronavirus.in.gov to register for a test.

Change in treatment playbook

The Associated Press reported Monday that U.S. health regulators say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant that now accounts for nearly all U.S. infections.

The Food and Drug Administration said it was revoking emergency authorization for both drugs, which were purchased by the federal government and given to millions of Americans with COVID-19. If the drugs prove effective against future variants, the FDA said it could reauthorize their use.

The regulatory move was expected because both drugmakers had said the infusion drugs are less able to target omicron due to its mutations.

Omicron’s resistance to the two leading monoclonal antibody medicines has upended the treatment playbook for COVID-19 in recent weeks.

Doctors have alternate therapies to battle early COVID-19 cases, including two new antiviral pills from Pfizer and Merck, but both are in short supply. An antibody drug from GlaxoSmithKline that remains effective also is in short supply.

The drugs are not a substitute for vaccination and are generally reserved for people who are the most vulnerable, including seniors, transplant recipients and those with conditions like heart disease and diabetes.

Both Regeneron and Lilly previously announced they were developing new antibodies that target omicron.

The move comes days after regulators broadened the use of remdesivir — the first drug approved for COVID-19 — to treat more patients. On Friday, the FDA expanded the antiviral’s approval to include adults and children with early COVID-19 who face a high risk of ending up in the hospital. Remdesivir previously had been limited to hospitalized patients.